Drug Search Results
More Filters [+]

Marimastat

Alternative Names: marimastat
Latest Update: 2024-04-26
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MMP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boston Children's Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Marimastat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Small Cell Lung Cancer|Breast Cancer|Non-Small-Cell Lung Cancer

Phase 1: Vascular Malformations

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CDR0000065585

P3

Completed

Breast Cancer

2004-12-01

BR12

P3

Completed

Small Cell Lung Cancer

2001-02-13

03-04-052R

P1

Completed

Vascular Malformations

None

CDR0000065284

P3

Completed

Non-Small-Cell Lung Cancer

None

Recent News Events